Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study

Published:2018-12 Issue: Volume:105 Page:114-126
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Namikawa Kenjiro,Kiyohara Yoshio,Takenouchi Tatsuya,Uhara Hisashi,Uchi Hiroshi,Yoshikawa Shusuke,Takatsuka Sumiko,Koga Hiroshi,Wada Naoko,Minami Hironobu,Hatsumichi Masahiro,Asada Suguru,Namba Yoshinobu,Yamazaki Naoya

Funder

Ono Pharmaceutical Co., Ltd.

Bristol-Myers Squibb

Merck Sharp & Dohme

Novartis Pharmaceutical

Toray Industries

Takara Bio Inc.

Eisai Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Novartis Pharma K.K.

Merck Serono

Amgen Inc.

Novartis Pharma K.K

Bayer AG

Daiichi Sankyo Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Taiho Pharmaceutical

Boehringer Ingelheim

Kyowa Hakko Kirin Co., Ltd.

Lilly, Nippon Chemiphar

Pfizer Inc.

Sanofi S.A.

Takeda Pharmaceutical Co., Ltd.

Asahi-Kasei Corporation

Astellas Pharma Inc.

AstraZeneca

Nippon Shinyaku Co. Ltd.

Taisho Toyama Pharmaceutical Co., Ltd.

Teijin Pharma Ltd.

Yakult Honsha Co., Ltd.

Ono Pharmaceutical Co., Ltd

Maruho Co., Ltd.

Pola Pharma Inc.

Mochida Pharmaceutical Co., Ltd.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application;Okazaki;Nat Immunol,2013

2. Pharmacological interventions for melanoma: comparative analysis using Bayesian meta-analysis;Yang;Oncotarget,2016

3. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors;Curran;Proc Natl Acad Sci U S A,2010

4. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models;Selby;J Clin Oncol,2013

5. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological features, response patterns, outcomes and BRAF status in patients with advanced acral melanoma: a preliminary Peruvian study;ecancermedicalscience;2024-08-27

2. Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance;Cancers;2024-04-19

3. Immunotherapy of Human Melanoma: Past, Present, Future;Current Medicinal Chemistry;2024-03-06

4. Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?;The Journal of Dermatology;2024-02-15

5. Combined Pd-1 and Ctla-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3